Is Masseter Botox FDA Approved? sBLA Acceptance Is Not a US Indication

No. Masseter Botox is not FDA-approved in the United States as of 25 August 2026.

On 4 August 2026, the U.S. Food and Drug Administration (FDA) accepted for review a supplemental Biologics License Application (sBLA) submitted by Allergan Aesthetics (an AbbVie company) for BOTOX Cosmetic (onabotulinumtoxinA, BLA 103000). The proposed indication is for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults.

Filing acceptance means the FDA determined the application is sufficiently complete to begin substantive scientific review. Acceptance is not an FDA approval, does not create an FDA-labeled dose, and does not establish a fifth aesthetic indication.

The current United States Prescribing Information (US PI) for BOTOX Cosmetic lists exactly four adult aesthetic indications: glabellar lines, lateral canthal lines (crow's feet), forehead lines, and platysma bands. Masseter muscle prominence does not appear anywhere in the approved label. Until the FDA issues an approval letter and updates the product's official prescribing information, all masseter injections for jawline slimming or lower facial contouring in the United States remain off-label.

---

Direct Comparison: Current US Approval Status vs. sBLA Filing

---

What Did the FDA Actually Do on 4 August 2026? Acceptance vs. Approval

In regulatory medicine, the gap between application acceptance and marketing approval is substantial:

1. sBLA submission. The manufacturer files a supplemental Biologics License Application.
2. Filing acceptance (4 August 2026). FDA judged the dossier complete enough to begin review. That is not a benefit-risk decision.
3. Substantive scientific review. Reviewers evaluate safety, efficacy, manufacturing, and proposed labeling on the PDUFA clock.
4. Regulatory action. Only an approval letter (or a Complete Response Letter) changes the US PI. Until that letter exists, masseter is not a labeled indication.

When a manufacturer submits an sBLA, the FDA performs a 60-day filing review to confirm that the dossier contains the required clinical, statistical, safety, and manufacturing documentation. On 4 August 2026, the FDA confirmed that Allergan's submission for MMP met those threshold criteria and formally accepted the sBLA for review.

Acceptance triggers the standard review timeline under the Prescription Drug User Fee Act (PDUFA). During this period, FDA medical officers, biostatisticians, and clinical pharmacologists rigorously audit the underlying raw trial datasets, inspect clinical study sites, and scrutinize the proposed package insert wording.

The FDA may ultimately grant marketing approval, request additional post-marketing commitments, or issue a Complete Response Letter (CRL) if deficiencies are identified. Until a formal approval decision is rendered, any marketing claim that masseter Botox is "newly FDA-approved" is false.

---

The Four Current Labeled Indications for BOTOX Cosmetic

To understand what is missing from the label, consider what is currently included. Under BLA 103000, the FDA-approved package insert (DailyMed SPL setid 485d9b71-6881-42c5-a620-a4360c7192ab) authorizes BOTOX Cosmetic exclusively for four upper- and lower-facial muscle groups:

1. Glabellar Lines: Moderate to severe vertical frown lines associated with corrugator and/or procerus muscle activity in adults (Labeled dose: 20 Units total across 5 intramuscular injection sites).
2. Lateral Canthal Lines (Crow's Feet): Moderate to severe lines associated with orbicularis oculi muscle activity in adults (Labeled dose: 24 Units total across 6 injection sites, 3 per side).
3. Forehead Lines: Moderate to severe horizontal lines associated with frontalis muscle activity in adults, administered in conjunction with glabellar treatment (Labeled dose: 20 Units frontalis + 20 Units glabella = 40 Units total).
4. Platysma Bands: Moderate to severe vertical platysma bands associated with platysma muscle activity in adults (labeling expansion dated 18 October 2024; labeled dose: 26, 31, or 36 Units across 18, 23, or 28 injection sites depending on band count). For full details on this fourth expansion, see our analysis of Botox for platysma bands and neck rejuvenation.

If the current sBLA is approved, masseter muscle prominence will become BOTOX Cosmetic's fifth aesthetic indication and make it the first neuromodulator in the United States with an FDA-approved jawline contouring label. For a broader landscape of approved neurotoxin labels, see our guide comparing types of Botox and FDA-approved neurotoxins.

---

The Pivotal Phase 3 Trials: Mapping M21-416 and M21-417

The regulatory dossier submitted in the sBLA rests primarily on two completed, double-blind, randomized, placebo-controlled Phase 3 clinical trials:

1. Study M21-416 (ClinicalTrials.gov ID: NCT06387394)

• Design: Multicenter, randomized, double-blind, placebo-controlled trial evaluating onabotulinumtoxinA in adult participants with moderate to very marked masseter muscle prominence.
• Enrollment: 202 actual subjects enrolled across multiple study centers.
• Study Completion Date: 25 November 2025.
• Primary Endpoint: Proportion of subjects achieving treatment success at Day 90, defined as a composite ≥2-grade improvement from baseline on both the clinician-rated Masseter Muscle Prominence Scale (MMPS) and the patient-reported Masseter Muscle Prominence Scale-Patient (MMPS-P).

2. Study M21-417 (ClinicalTrials.gov ID: NCT06399718)

• Design: Replicate multicenter, randomized, double-blind, placebo-controlled Phase 3 trial.
• Enrollment: 207 actual subjects enrolled.
• Study Completion Date: 10 November 2025.
• Primary Endpoint: Identical composite Day-90 MMPS and MMPS-P 2-grade responder threshold.

Manufacturer-Disclosed Results vs. FDA Regulatory Review

In its 4 August 2026 announcement, AbbVie disclosed that both pivotal trials met their primary endpoints:

• Study M21-416: Superiority over placebo at the company-reported p = 0.0046.
• Study M21-417: Superiority over placebo at the company-reported p = 0.0014.
• Patient satisfaction: AbbVie reported that approximately twice as many onabotulinumtoxinA-treated subjects were satisfied with their lower facial appearance compared with placebo.

Methodological context: These p-values and the “twice as many” satisfaction line are manufacturer top-line disclosures. They are not yet in a peer-reviewed paper or an FDA Summary Basis of Regulatory Action. Responder percentages and subgroup analyses are not in a public SSED. Do not treat the press p-values as a labeled benefit.

Crucial Trial Identifiers: Avoiding Common Lookalike NCT Numbers

When researching clinical databases, several other onabotulinumtoxinA masseter studies exist that must not be confused with the US sBLA Phase 3 pair:

• NCT06387394 (M21-416, n=202): US registration Phase 3 named in the sBLA press (completed 25 November 2025).
• NCT06399718 (M21-417, n=207): US registration Phase 3 named in the sBLA press (completed 10 November 2025).
• NCT06068855 (M23-123, n=249): International Phase 3 study in masseter prominence.
• NCT06137287 (M22-080, n=259): Japan registration Phase 3 study.
• NCT03861936 (Phase 2b, n=150): Earlier US dose-ranging study (published in ASJ 2025).
• NCT04073303 (Study 1789-301-008, n=377): Multicenter Asian registration study.

---

What Did the Published Phase 2b Trial Actually Measure?

Before initiating the Phase 3 trials, Allergan completed a Phase 2b multicenter, double-blind, placebo-controlled dose-ranging trial (NCT03861936), published in the Aesthetic Surgery Journal (ASJ 2025; PMC12548054).

Study Parameters and Design

• Cohort: 150 randomized subjects (modified intent-to-treat population, n=145).
• Treatment arms:
  • 48 Units onabotulinumtoxinA (n=53)
  • 72 Units onabotulinumtoxinA (n=46)
  • Placebo (n=46)
• Injection technique: Six intramuscular injections (three per masseter) into the area of maximal bulge, as described in the published protocol.

Key published efficacy outcomes at Day 90

• Investigator MMPS Grade ≤3 (the primary endpoint):
  • 48 Units: 90.6% (48/53)
  • 72 Units: 91.3% (42/46)
  • Placebo: 21.7% (10/46)
• Investigator ≥2-grade MMPS improvement (a more stringent secondary endpoint, not the Phase 3 composite):
  • 48 Units: 66.0% (35/53)
  • 72 Units: 71.7% (33/46)
  • Placebo: 10.9% (5/46)

Why These Trial Doses Are Not a Labeled Prescription

While the Phase 2b data demonstrate biological activity and muscular reduction, 48 Units or 72 Units is not an FDA-labeled dose. Clinical trials test fixed investigational unit bands. Until a PI names masseter, there is no labeled unit count or injection template. Individualized dosing belongs to the treating clinician and the existing masseter technique page, not this status article.

---

Aesthetic MMP vs. TMJ/TMD Pain: Clearing the Regulatory Confusion

A primary driver of consumer confusion on search engines is the conflation of aesthetic masseter prominence (MMP) with temporomandibular joint disorders (TMD/TMJ).

The "FDA-Approved Botox for TMJ" Myth

Numerous dental and med-spa websites publish landing pages titled "FDA-Approved Botox for TMJ." This claim is completely false.

The FDA has never approved Botox—or any other botulinum toxin product—for the treatment of TMJ disorders, bruxism, or myofascial jaw pain. When dentists or oral surgeons inject Botox into the masseter, temporalis, or lateral pterygoid muscles for clenching or jaw pain, they are doing so off-label.

The TMJ Association and Mandibular Bone Safety

The TMJ Association (TMJA) and maxillofacial researchers have urged caution regarding high-dose, recurring masseter injections. In animal models and exploratory human observational studies, severe chemo-denervation of the masticatory muscles can reduce functional mechanical loading on the mandible, leading to localized osteopenia or alterations in mandibular condylar bone density.

While repeated aesthetic masseter injections are widely used off-label, patients seeking pain relief should not treat masseter Botox as an FDA-vetted cure for joint disease. Bone-loading concerns in the TMJ literature are a reason to ask about indication, dose, and follow-up — not a reason to read a dental “FDA-approved TMJ Botox” page as an MMP approval.

---

International Clearances Are Not US Labels: The China Precedent

Patients searching medical literature often encounter news of official approvals overseas. Most notably, on 11 September 2024, Allergan Aesthetics announced that China's National Medical Products Administration (NMPA) had approved BOTOX for the temporary improvement of moderate to severe masseter muscle prominence.

While international regulatory actions reflect real scientific data, foreign drug approvals grant zero legal authorization in the United States. The FDA operates under distinct statutory authority (the U.S. Federal Food, Drug, and Cosmetic Act and the Public Health Service Act), requires independent application dossiers, and enforces its own labeling standards. A patient in New York, Chicago, or Los Angeles is treated under U.S. FDA regulatory jurisdiction.

---

Off-Label Practice in the United States: Clinical Realities and Tradeoffs

Although masseter Botox is not FDA-approved, off-label prescribing by licensed healthcare providers is entirely legal and common in the United States.

Once a drug is approved for any indication (such as glabella or platysma), a licensed prescriber may legally use professional medical judgment to administer it at unapproved anatomical sites, subject to state scope-of-practice rules. For an overview of legal boundaries and consent requirements, read our complete guide to off-label aesthetic injections.

However, off-label status means the FDA has not validated the specific safety margins, standardized dosing, or injection templates in a formal package insert. Patients must evaluate specific anatomical tradeoffs:

1. Temporary Bite-Force Reduction and Chewing Fatigue

The masseter is one of the primary muscles of mastication. Paralyzing a substantial portion of its motor endplates temporarily reduces maximum voluntary bite force. Patients frequently experience mild fatigue when chewing tough foods (such as steak, bagels, or raw carrots) for 2 to 6 weeks following treatment.

2. Risorius Diffusion and Smile Asymmetry

If the injector places the needle too anteriorly (beyond the anterior border of the masseter) or too superficially, the neurotoxin can diffuse into the risorius muscle or the zygomaticus major. This produces an asymmetrical, unnatural smile where the corner of the mouth fails to retract during smiling. This complication cannot be reversed with hyaluronidase and resolves only when the toxin naturally degrades (typically 8 to 14 weeks).

3. Jowl Prominence and Lower Face Sagging

Reducing the volume of the masseter muscle reduces the structural framework of the lateral lower face. In patients under age 35 with firm skin elasticity, the skin retracts smoothly over the newly slender jawline.

However, in patients with pre-existing cutaneous laxity, thin dermis, or age-related tissue descent, deflating the underlying masseter can cause the overlying soft tissue to collapse forward, exacerbating jowling and deepening the marionette lines. For anatomical guidelines, review our detailed guide on masseter Botox slimming and complication avoidance.

4. Paradoxical Bulging

If an injection only treats the superficial muscle belly while leaving deep muscular fibers active, the deep masseter compensates by contracting forcefully, creating a visible, firm bulge when clenching. This is corrected with a targeted touch-up into the hyperactive deep fibers.

---

Pricing and Cost Dynamics for Masseter Injections

Because masseter prominence is an off-label aesthetic procedure, it is cash-pay and not a covered medical benefit for jaw slimming.

There is still no FDA-labeled unit count. Practice ranges on this site’s existing masseter technique page are typically 20–30 Units per side (about 40–60 Units total), at two to three injection points per muscle — clinical experience, not a package-insert dose. Session quotes usually follow per-unit or per-area pricing; see Botox price per unit vs area. Visible slimming often lags the toxin’s onset because atrophy takes weeks, and the muscle can regain bulk over subsequent months. Those timelines belong on the masseter technique page, not as proof of US approval.

---

Questions to Ask Before Booking Masseter Botox

If a provider or clinic advertises "FDA-approved jawline slimming" or recommends masseter injections, bring these direct questions to your consultation:

1. "Are you aware that BOTOX Cosmetic is currently under sBLA review and remains off-label for masseter prominence in the United States?"
   Why to ask: Assesses whether the clinic maintains rigorous regulatory honesty rather than repeating inaccurate marketing copy.
2. "How do you palpate and mark the anterior and superior borders of my masseter to avoid the risorius muscle and parotid gland?"
   Why to ask: Verifies anatomical safety to prevent smile distortion and dry mouth complications.
3. "Am I a candidate for jaw slimming, or will reducing masseter volume worsen my jowls or lower facial skin laxity?"
   Why to ask: Prevents cosmetic disappointment in patients who require skin-tightening rather than muscle debulking.
4. "How many units do you plan to inject per side, and how many distinct intramuscular injection points will you use?"
   Why to ask: Confirms the injector follows evidence-based multipoint distribution (typically 3 to 4 points per side) rather than dumping high volume in a single bolus.
5. "If I develop paradoxical bulging upon clenching at two weeks, what is your policy for assessment and touch-up dosing?"
   Why to ask: Clarifies follow-up care for deep-fiber compensation.

---

Frequently Asked Questions

Is masseter Botox FDA approved?

No. As of 25 August 2026, masseter Botox is not FDA-approved in the United States. On 4 August 2026, the FDA accepted a supplemental Biologics License Application (sBLA) from Allergan Aesthetics for review, but active review is not an approval.

Did FDA approve Botox for jaw slimming in 2026?

No. Media headlines reporting an "FDA nod" or "FDA action" in August 2026 refer to the FDA accepting an sBLA filing for review. The product label has not changed, and no jaw-slimming indication has been granted.

Is Botox for TMJ FDA approved?

No. Botox is not FDA-approved for TMJ disorders, teeth grinding (bruxism), or jaw pain. Injections for TMJ are performed off-label under clinician discretion.

What is masseter muscle prominence (MMP)?

Masseter muscle prominence refers to enlargement or hypertrophy of the masseter muscles, causing a widened, square lower face. The proposed sBLA evaluates BOTOX Cosmetic for the temporary reduction of this muscular prominence.

When will masseter Botox be FDA approved in the US?

FDA has not published a PDUFA goal date in the 4 August 2026 acceptance release. Standard review clocks for many sBLAs are on the order of months from receipt, but that is a process description, not a scheduled decision. Treat any “mid-2027 approval” claim as speculation until FDA posts an action.

How many units of Botox for masseter are FDA-approved?

Zero units are FDA-approved for the masseter. The published Phase 2b trial evaluated 48 Units and 72 Units total. Those are study doses, not a labeled dose. Off-label clinic ranges vary; they are not a substitute for an FDA injection template.

---

Sources

• Allergan Aesthetics (AbbVie), Newsroom: U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX Cosmetic for Masseter Muscle Prominence (4 August 2026): https://news.abbvie.com/2026-08-04-Allergan-Aesthetics-Announces-U-S-FDA-Acceptance-of-Supplemental-Biologics-License-Application-for-BOTOX-R-Cosmetic-for-Masseter-Muscle-Prominence
• U.S. Food and Drug Administration / DailyMed: BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information, BLA 103000, Set ID 485d9b71-6881-42c5-a620-a4360c7192ab (Effective 18 October 2024): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab
• ClinicalTrials.gov: Study M21-416 Evaluating OnabotulinumtoxinA for the Treatment of Masseter Muscle Prominence (NCT06387394, n=202): https://clinicaltrials.gov/study/NCT06387394
• ClinicalTrials.gov: Study M21-417 Evaluating OnabotulinumtoxinA for the Treatment of Masseter Muscle Prominence (NCT06399718, n=207): https://clinicaltrials.gov/study/NCT06399718
• PMC / Aesthetic Surgery Journal: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of OnabotulinumtoxinA for Masseter Muscle Prominence (ASJ 2025; PMC12548054): https://pmc.ncbi.nlm.nih.gov/articles/PMC12548054/
• FDA Drugs@FDA Database: Biologics License Application BLA 103000 (BOTOX / BOTOX Cosmetic): https://www.accessdata.fda.gov/scripts/cder/daf/
• The TMJ Association (TMJA): Patient Safety and Bone-Related Effects of Botulinum Toxin for TMJ Disorders: https://tmj.org/patient-bone-related-safety-of-botox-for-treatment-of-tmj-disorders/
• Allergan Aesthetics, International Regulatory Announcement: Approval of BOTOX for Masseter Muscle Prominence by National Medical Products Administration (China, 11 September 2024): https://news.abbvie.com/2024-09-11-Allergan-Aesthetics-Launches-BOTOX-R-Cosmetic-onabotulinumtoxinA-for-Masseter-Muscle-Prominence-MMP-in-Adults-in-China